Company intelligence / Profile preview

Epygen Biotech

Patalganga, Maharashtra, India

Ownership: Private
Employees: ~125
Development stage: Other

Overview

Recombinant streptokinase (rSK) biosimilar licensed from CSIR-IMTECH, launched in India for myocardial infarction; further phase I/II trials for stroke and COVID-19 RBD-based vaccine. Pegfilgrastim, bevacizumab, teriparatide, and monoclonal antibodies are in preclinical/clinical development or manufacturing for biosimilar launch.

Therapeutic areas: OncologyCardiovascularInfectious DiseasesEndocrinology
Modalities: Recombinant proteinMonoclonal antibodyVaccineInsulin analoguesHuman hormoneSmall molecule
Industry: Biotech

Partnerships

CSIR-IMTECH (technology license for streptokinase)Dyadic International (vaccine platform collaboration)Department of Biotechnology, Government of India (COVID-19 vaccine funding)

Beyond the preview

Go deeper on Epygen Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epygen Biotech.

Explore the full profile